FDA

Standard Homeopathic recalls Hyland’s teething tablets

Standard Homeopathic recalls Hyland’s teething tablets

Los Angeles-based Standard Homeopathic Co. has issued a nationwide recall for any remaining packages of its teething tablets after regulators warned that the medicine has inconsistent levels of an herb that might be poisonous.

Standard Homeopathic stopped producing and supplying Hyland’s teething tablets in October last year, and notified distributors as well as stores to return the tablets. Consumers who might have already purchased the tablets were advised to throw them out.

News: 
Location: 
Company: 

FDA approves 23andMe’s genetic testing kit

FDA approves 23andMe’s genetic testing kit

The U.S. Food & Drug Administration (FDA) has finally approved 23andMe’s personal genetic test for certain diseases, including Parkinson’s, Alzheimer’s, and celiac diseases.

The FDA said in statement that the genetic test assess genetic risk for the aforementioned conditions but does not diagnose them. The federal agency also urged people to use their results to help make decisions regarding lifestyle choices and to inform discussions with a healthcare expert.

News: 
Location: 
Company: 

FDA investigating Vulto cheese-linked listeria outbreak

FDA investigating Vulto cheese-linked listeria outbreak

The U. S. Food & Drug Administration (FDA) has confirmed that it has launched an investigation into the most recent multistate outbreak of listeriosis that has been linked to soft raw milk cheese produced by Vulto Creamery.

Vulto Creamery recalled its Heinennellie, Willowemoc, Miranda and Ouleout raw milk cheeses on Tuesday, after at least two deaths and half a dozen hospitalizations were linked to the products. Walton Umber, Andes, Blue Blais and Hamden cheeses are also being recalled.

News: 
Location: 
Company: 

EMA gives conditional approval to AbbVie’s cancer drug

EMA gives conditional approval to AbbVie’s cancer drug

An advisory committee of the European Medicines Agency (EMA) on Friday gave its conditional backing to AbbVie Inc.’s venclyxto, a drug developed to treat a form of blood cancer.

News: 
Location: 
Company: 

Pages